StockData
Lakefront Biotherapeutics NV logo

Lakefront Biotherapeutics NV (LKFT) stock

LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$34.07−0.32 (-0.93%)

Close on Nov 18, 2026Market cap $2.25BP/E 6.3Yield –

Lakefront Biotherapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was €295.04M. The highest annual figure on record is €368.75M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025€295.04M–
FY2024Dec 31, 2024-€188.34M–
FY2023Dec 31, 2023-€88.26M–
FY2022Dec 31, 2022-€131.06M–
FY2021Dec 31, 2021-€171.57M–
FY2020Dec 31, 2020-€178.63M-148.4%
FY2019Dec 31, 2019€368.75M–
FY2018Dec 31, 2018-€47.08M–
FY2017Dec 31, 2017-€89.80M–
FY2016Dec 31, 2016-€11.49M–
FY2015Dec 31, 2015-€89.44M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2021Jun 30, 2021-€46.75M–
Q2 FY2020Jun 30, 2020-€88.17M–
Q2 FY2019Jun 30, 2019-€44.37M–
Q2 FY2018Jun 30, 2018-€33.75M–
Q2 FY2017Jun 30, 2017-€21.68M–

More Lakefront Biotherapeutics figures

See a number that looks wrong?